Evotec (OTCMKTS:EVTCY) Stock Price Crosses Above 50-Day Moving Average - Time to Sell?

Key Points

• Evotec's share price crossed above its 50-day moving average (50‑day = $2.90), trading as high as $3.16 and last at $3.14 on volume of 53,524 shares, though it remains below the 200‑day MA of $3.25.
• The company has a market capitalization of $1.04 billion and a low P/E of 7.66, with a debt-to-equity ratio of 0.53 and strong short-term liquidity (current ratio 2.57, quick ratio 2.50).
• Evotec is a Germany-based biotechnology firm that partners with pharmaceutical and biotech companies to provide integrated drug discovery and development services across target ID, screening, medicinal chemistry, preclinical development and manufacturing support.

Evotec SE (OTCMKTS:EVTCY - Get Free Report)'s share price crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.90 and traded as high as $3.16. Evotec shares last traded at $3.14, with a volume of 53,524 shares.

Evotec Trading Down 0.3%

The company's 50 day simple moving average is $2.90 and its 200 day simple moving average is $3.25. The firm has a market cap of $1.04 billion, a price-to-earnings ratio of 7.66 and a beta of 0.98. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.57 and a quick ratio of 2.50.

About Evotec

Evotec SE is a Germany-based biotechnology company specializing in drug discovery alliance and development partnerships. Headquartered in Hamburg, the company collaborates with pharmaceutical and biotechnology firms to deliver integrated solutions across the drug discovery and development continuum. Its offerings span from target identification and validation to lead optimization, preclinical development and manufacturing support.

The company's platform combines expertise in assay development, high-throughput screening, medicinal chemistry, in vivo pharmacology and safety assessment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.